Atkins MB - Search Results

1

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.

Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC. Zea AH, et al. Among authors: atkins mb. Cancer Res. 2005 Apr 15;65(8):3044-8. doi: 10.1158/0008-5472.CAN-04-4505. Cancer Res. 2005. PMID: 15833831

2

Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case report.

Sauter NP, Atkins MB, Mier JW, Lechan RM. Sauter NP, et al. Among authors: atkins mb. Am J Med. 1992 Apr;92(4):441-4. doi: 10.1016/0002-9343(92)90278-j. Am J Med. 1992. PMID: 1558092

3

Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapy.

Bergstrom RW, Atkins MB, Mier JW, Palmer JP. Bergstrom RW, et al. Among authors: atkins mb. J Clin Lab Immunol. 1990 Apr;31(4):189-93. J Clin Lab Immunol. 1990. PMID: 1967063

4

A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.

Sznol M, Mier JW, Sparano J, Gaynor ER, Weiss GR, Margolin KA, Bar MH, Hawkins MJ, Atkins MB, Dutcher JP, et al. Sznol M, et al. Among authors: atkins mb. J Biol Response Mod. 1990 Dec;9(6):529-37. J Biol Response Mod. 1990. PMID: 2074439 Clinical Trial.

5

Lymphokine-activated killer cell generation and recovery. Comparison of an automated cell processing device and a manual procedure.

Ryan T, Atkins MB, Mier JW, Berkman EM. Ryan T, et al. Among authors: atkins mb. Transfusion. 1989 Jul-Aug;29(6):491-5. doi: 10.1046/j.1537-2995.1989.29689318445.x. Transfusion. 1989. PMID: 2787549

6

Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells.

Mier JW, Aronson FR, Numerof RP, Vachino G, Atkins MB. Mier JW, et al. Among authors: atkins mb. Pathol Immunopathol Res. 1988;7(6):459-76. doi: 10.1159/000157075. Pathol Immunopathol Res. 1988. PMID: 2976936 Review.

7

Effects of malignancy and interleukin-2 infusion on gut macromolecular permeability.

Ryan CM, Atkins MB, Mier JW, Gelfand JA, Tompkins RG. Ryan CM, et al. Among authors: atkins mb. Crit Care Med. 1995 Nov;23(11):1801-6. doi: 10.1097/00003246-199511000-00003. Crit Care Med. 1995. PMID: 7587254 Clinical Trial.

8

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW, et al. Margolin K, et al. Among authors: atkins mb. J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):147-53. doi: 10.1097/00002371-199402000-00009. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8136948 Clinical Trial.

9

Mechanisms of action and toxicity of immunotherapy with cytokines.

Mier JW, Atkins MB. Mier JW, et al. Among authors: atkins mb. Curr Opin Oncol. 1993 Nov;5(6):1067-72. doi: 10.1097/00001622-199311000-00020. Curr Opin Oncol. 1993. PMID: 8305541 Review.

10

Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy.

Tilg H, Atkins MB, Dinarello CA, Mier JW. Tilg H, et al. Among authors: atkins mb. Cytokine. 1995 Oct;7(7):734-9. doi: 10.1006/cyto.1995.0087. Cytokine. 1995. PMID: 8580384 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

471 results

Search Page

Filters